Cambridge Cognition Holdings PLC Board Changes (0028X)
25 April 2019 - 4:01PM
UK Regulatory
TIDMCOG
RNS Number : 0028X
Cambridge Cognition Holdings PLC
25 April 2019
25 April 2019
Cambridge Cognition Holdings Plc
("Cambridge Cognition" or the "Company")
Board Changes
Cambridge Cognition Holdings plc ("the Company"), which develops
and markets neuroscience technology to assess brain health,
announces a number of changes to the Board of Directors which will
take effect following the Annual General Meeting ("AGM") scheduled
for 23 May 2019, subject to approval of shareholders.
Both Michael Lewis and Nicholas Kerton who will retire by
rotation at the forthcoming AGM will not offer themselves for
re-election.
Steven Powell will retire by rotation at the forthcoming AGM and
offer himself for re-election. Immediately following the AGM he
will step down as Chief Executive Officer but continue as a
Non-Executive Director and will take over as Chairman of the Board
of Directors. In addition to his Chairman duties he will continue
to play a significant role in key long-term corporate and R&D
strategies.
Matthew Stork, the Company's recently appointed Chief Operating
Officer, will join the Board as Chief Executive Officer. He has
expertise in a broad range of healthcare sectors including
healthcare IT (including AI), diagnostic imaging, clinical service
delivery and pharmaceuticals. He has held executive roles at the
InHealth Group, General Electric, ArjoHuntleigh, Toshiba Medical
Systems and Smith & Nephew.
The Company will seek to appoint an additional independent
Non-Executive Director within the next three months.
Steven Powell, Chief Executive Officer, commented:
"Mike Lewis and Nick Kerton were both appointed as Directors of
the Company on 12 April 2013 as the Company listed on AIM. Mike has
been Chairman of the Board since 8 May 2014 and Nick was Chief
Executive Officer from September 2013 until the end of 2015. Both
Mike and Nick retire from the company with our thanks for their
service over the past six years.
"Matthew and I have had the benefit of working together for the
past few months and Matthew inherits an exciting and innovative
business which has made good progress in penetrating its core
cognitive assessment and digital health markets. Matthew's
experience in healthcare and pharmaceuticals will bring a fresh
commercial perspective to the business and we will be working
together to accelerate the growth of the business."
Enquiries:
Cambridge Cognition Holdings plc www.cambridgecognition.com
Steven Powell, Chief Executive Officer Tel: 01223 810 700
Nick Walters, Chief Financial Officer press@camcog.com
finnCap Ltd (Nomad and Joint Broker)
Tel: 020 7220 0500
Geoff Nash/ Simon Hicks (Corporate Finance)
Alice Lane (Corporate Broking)
Dowgate Capital Limited (Joint Broker)
Tel: 0203 903 7715
David Poutney/ James Serjeant
IFC Advisory Ltd (Financial PR and Tel: 0203 934 6630
IR)
Tim Metcalfe / Miles Nolan / Zach Cohen
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOACKQDPPBKDNQB
(END) Dow Jones Newswires
April 25, 2019 02:01 ET (06:01 GMT)
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From Apr 2024 to May 2024
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From May 2023 to May 2024